Locations:

Preventive Cardiology

yellow and red illustration of blood cells moving through a blood vessel

First-in-Human Data Show One siRNA Can Lower Both LDL-C and Triglycerides

Early results for ARO-DIMER-PA point to a more streamlined way to treat mixed hyperlipidemia

two side-by-side medical illustrations with red trend line overlays

Lipoprotein(a) Reduction With Pelacarsen Has No Impact on Cardiac Events, Lp(a)HORIZON Finds

But unexpected results are ‘not the end of the story’ for Lp(a) lowering, investigators say

illustrated human gut with microbes and an overlay of a rhythm tracing

TMAO Shown to Be a Modifiable Risk Factor for Atrial Fibrillation

Bench-to-bedside study identifies mechanism and potential therapeutic target

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

human intestines with inset showing gut microbes

TMAO Emerges as a Biomarker for AAA Risk

Elevated levels of the gut microbial metabolite predict prevalence and adverse outcomes in community-based study

stylized illustration of cholesterol particle floating in bloodstream

Novel siRNA Produces Deep, Durable Reduction in Lp(a)

Phase 1 trial shows up to 97% decrease through 48 weeks with good tolerability

converging lines on a graph pointing downward

Oxidized Phospholipids Track Closely With Lp(a) Reductions in Clinical Trial

Post hoc ALPACA analysis boosts biological rationale for ongoing outcomes trial of lepodisiran

sight picture overlaid on DNA double helix

Positive Effects of CRISPR-Cas9 Gene Editing for Dyslipidemia Endure Through 1 Year

Durability findings propel potential one-time treatment approach to phase 1b testing

illustrated platelets forming a clot in a blood vessel

Bempedoic Acid Appears to Curb VTE Risk in Statin-Intolerant Patients

Post hoc analysis of CLEAR Outcomes trial bolsters its case as a statin alternative

doctor taking pulse of a woman in an exam room

Counseling Patients on the New Cholesterol Guideline: What Providers Should Know

How to talk about lifetime risk, treatment goals, Lp(a) testing, statin skepticism and more

BackPage 1 of 6Next

Advertisement

Ad